Mesenchymal Stem Cell-Derived Exosomes in Alzheimer’s and Parkinson’s Disease: Emerging Therapeutic Potential

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

Recent investigations suggest that exosomes derived from mesenchymal stem cells (MSCs) may offer therapeutic benefit in neurodegenerative disorders, particularly Parkinson’s disease (PD) and Alzheimer’s disease (AD). MSCs are multipotent stromal cells present in several tissues, including bone marrow, adipose tissue, dental pulp, placenta, and umbilical cord. These cells release extracellular vesicles, notably exosomes, which carry signaling molecules, cytokines, enzymes, and microRNAs (miRNAs). Due to their biological stability and functional properties, MSC-derived exosomes are increasingly studied as potential therapeutic agents for neurological conditions.

Mechanisms of Action

MSCs exert their effects through paracrine activity, largely mediated by secreted bioactive products collectively referred to as the secretome. This includes chemokines, growth factors, cytokines, extracellular vesicles, and proteins that promote neuroprotection, immunomodulation, and neural differentiation. Of particular interest is the ability of exosomal miRNAs to regulate gene expression and maintain cellular homeostasis.

In AD, MSC-derived exosomes show high levels of neprilysin, an amyloid β-degrading enzyme, which reduces amyloid plaque burden and slows disease progression. Additionally, MSCs enhance autophagy, leading to decreased amyloid β accumulation and improved neuronal survival. In PD, these exosomes have been shown to reduce neuroinflammation and suppress α-synuclein aggregation, a key pathological feature of the disease.

Experimental Evidence

Preclinical studies demonstrate several therapeutic effects of MSC-derived exosomes:

• Neuroprotection and Regeneration: Administration in rodent models reduces neuroinflammation, enhances axonal growth, and promotes synaptic repair.
• Behavioral Improvement: In PD models, exosome therapy improves motor function and decreases α-synuclein levels.
• Memory and Cognition: In AD models, MSC treatment enhances neurogenesis, improves memory function, and reduces cognitive decline.
• Crossing the Blood–Brain Barrier: MSC-derived products have shown an ability to penetrate the blood–brain barrier, supporting their feasibility for central nervous system therapy.

Routes of Administration

Multiple delivery strategies are under investigation:

1. Direct Intracranial Transplantation: Placement into affected regions such as the substantia nigra, striatum, and subthalamic nucleus demonstrates positive outcomes in experimental PD.
2. Migration to Injury Sites: MSCs exhibit tropism for damaged areas, which enhances repair potential.
3. Intranasal Delivery: Preclinical models reveal effective transport to brain regions including the hippocampus, cerebellum, striatum, and amygdala, with sustained presence for several months following administration. This minimally invasive method represents a promising alternative to surgical transplantation.

Clinical Research Status

Despite encouraging preclinical data, clinical translation remains limited. A small number of registered trials are evaluating MSC-based therapies for AD and PD. Notably, one trial (NCT04388982) is assessing the safety and efficacy of MSC-derived exosomes in individuals with mild-to-moderate dementia. More comprehensive clinical investigations are needed to establish therapeutic viability, dosing regimens, and long-term outcomes.

Conclusion

MSCs and their exosome derivatives present a novel, biologically active therapeutic approach for AD and PD. Their neuroprotective, anti-inflammatory, and regenerative properties make them promising candidates for future clinical application. While preclinical findings are robust, clinical validation is still in its early stages. Ongoing and future trials will be critical in determining the translational potential of MSC-derived exosomes as disease-modifying treatments in neurodegeneration.

REFERENCES

1. Vilaça-Faria, H., Salgado, A. J., & Teixeira, F. G. (2019). Mesenchymal Stem Cells-derived Exosomes: A New Possible Therapeutic Strategy for Parkinson’s Disease?. Cells, 8(2), 118. https://doi.org/10.3390/cells8020118
2. Shin, J. Y., Park, H. J., Kim, H. N., Oh, S. H., Bae, J. S., Ha, H. J., & Lee, P. H. (2014). Mesenchymal stem cells enhance autophagy and increase β-amyloid clearance in Alzheimer disease models. Autophagy, 10(1), 32–44. https://doi.org/10.4161/auto.26508
3. Park, H. J., Lee, P. H., Bang, O. Y., Lee, G., & Ahn, Y. H. (2008). Mesenchymal stem cells therapy exerts neuroprotection in a progressive animal model of Parkinson’s disease. Journal of neurochemistry, 107(1), 141–151. https://doi.org/10.1111/j.1471-4159.2008.05589.x
4. Li, Q., Wang, Z., Xing, H., Wang, Y., & Guo, Y. (2021). Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson’s disease. Molecular therapy. Nucleic acids, 23, 1334–1344. https://doi.org/10.1016/j.omtn.2021.01.022
5. Jeong, H., Kim, O. J., Oh, S. H., Lee, S., Reum Lee, H. A., Lee, K. O., Lee, B. Y., & Kim, N. K. (2021). Extracellular Vesicles Released from Neprilysin Gene-Modified Human Umbilical Cord-Derived Mesenchymal Stem Cell Enhance Therapeutic Effects in an Alzheimer’s Disease Animal Model. Stem cells international, 2021, 5548630. https://doi.org/10.1155/2021/5548630

Boika, A., Aleinikava, N., Chyzhyk, V., Zafranskaya, M., Nizheharodava, D., & Ponomarev, V. (2020). Mesenchymal stem cells in Parkinson’s disease: Motor and nonmotor symptoms in the early posttransplant period. Surgical neurology international, 11, 380. https://doi.org/10.25259/SNI2332020